---
title: "Pharmacological Breakthrough: Ukrainian Scientists Synthesize Substance Against Superbugs"
description: "Scientists from the NAS of Ukraine's Institute of Cell Biology have obtained yeast strains producing antibacterial aminoriboflavin. The substance is active against MRSA, but requires scaling and investment."
date: 2026-10-25T08:17:28.077Z
lang: en
url: https://xab.info/en/posts/ukrainian-scientists-create-antibiotic-prototype
tags: [ukraine, biotechnology, medicine, antibiotics, nan-ukraine, innovation, science]
author: "Alexander Buran"
publisher: "XAB.info"
---

# Pharmacological Breakthrough: Ukrainian Scientists Synthesize Substance Against Superbugs

![Laboratory test tubes with blue liquid in a rack](https://xab.info/media/2026/10/25/ukrainskie-uchenye-sozdali-prototip-antibiotika/ukrainskie-uchenye-sozdali-prototip-antibiotika-1.webp)

## Key Points

- Yeast strains producing aminoriboflavin have been developed.
- The substance is active against methicillin-resistant Staphylococcus aureus.
- The development is currently at the laboratory sample stage.
- Serial production requires investment and preclinical trials.

Researchers from the Institute of Cell Biology of the National Academy of Sciences of Ukraine in Lviv have reported a significant step in the fight against antibiotic resistance. A group of scientists, led by Institute Director Kostyantyn Dmytruk, has successfully developed yeast strains capable of producing aminoriboflavin, a derivative of vitamin B2 that exhibits strong antibacterial activity. This discovery may provide the foundation for developing new drugs capable of attacking pathogens resistant to existing medicinal products.

### Effectiveness Against Resistant Pathogens

The key advantage of the discovered substance is its ability to act against methicillin-resistant Staphylococcus aureus (MRSA). This type of bacteria poses a serious threat to global medicine due to its resistance to most standard antibiotics, often leading to complications in the treatment of hospital-acquired infections. Laboratory data confirm that aminoriboflavin successfully suppresses the activity of such pathogens, opening perspectives for the creation of fundamentally new therapeutic agents.

### Technological Challenges and Development Stages

Kostyantyn Dmytruk emphasizes that current success has been achieved at the laboratory producer stage; there is a long way to go before a full-fledged medicine is created. Scientists need to optimize fermentation processes, significantly increase strain productivity, and develop complex technologies for isolating and purifying the substance to pharmaceutical purity standards. This will be followed by a cycle of preclinical studies on animals, where toxicity and pharmacokinetics will be evaluated, to be followed by clinical trials involving humans.

### Investment Climate and State Perspectives

Commercialization of the development requires significant investment, which is complicated by the low projected profitability for private pharmaceutical companies. According to the expert, without state support and active international partnership, the project risks remaining only a promising scientific platform. However, the experience of accelerated vaccine development during the COVID-19 pandemic proves that with proper resource concentration and political will, the path from the laboratory to the pharmacy shelf can be significantly shortened.

### Significance for the Healthcare System

Developing new antibiotics is a critically important task, as drug resistance in bacteria is recognized as one of the main threats to global health in the current decade. The success of Lviv biologists underscores the intellectual potential of Ukrainian academic science. Further development of this platform can not only strengthen the country's position in the global pharmaceutical market but also provide access to innovative treatment of critical infections, saving thousands of lives.

## Fact-Check & Sources

- [Во Львове ученые приблизились к созданию нового антибиотика: будет ли у Украины свой препарат](https://www.rbc.ua/ukr/news/lvovi-vcheni-nablizilisya-stvorennya-novogo-1792594518.html) - The information aligns with the publication on RBC-Ukraine, based on an interview with Kostyantyn Dmytruk, Director of the Institute of Cell Biology of the NAS of Ukraine.

## FAQ

### What exactly did the Lviv scientists discover?

Scientists have bred yeast strains that produce aminoriboflavin, a substance with high antibacterial activity that acts on resistant forms of staphylococcus.

### Can this substance be used as an antibiotic now?

No, the development is a laboratory producer. Transforming it into a drug requires optimization of purification, as well as preclinical and clinical trials.

### What are the main obstacles to creating the drug?

The main obstacles are lack of funding and low interest from the private sector, requiring state support and international cooperation.